The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Palivizumab (Synagis; Abbott Laboratories), a humanized, monoclonal antibody, prevents lower respiratory tract infection by respiratory syncytial virus (RSV). RSV causes significant morbidity and mortality in young children worldwide and is particularly severe in pre-term infants, children with cardiopulmonary disease, and the immunosuppressed population. The first such genetically engineered agent...